Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Comparing the groups after 1 year, no statistically significant differences were seen except for the Ca++ levels: the decrease in Ca++ levels was significantly higher in the SG compared to the PG (− 0.22 vs. − 0.12 mmol/L; p = 0.004) (Table 3).Biochemical parameters: intra-group changes (baseline to 1 year) and comparison between groups after 1 yearPlacebo groupStrontium groupBetween-group after 1 yearBaseline1 yearpBaseline1 yearppPTH (pg/mL)123.9 (90.8; 162.2)36.2 (15.9; 51.1)< 0.001141.3 (97.4; 162.9)29.5 (± 23.5; 41.0)< 0.0010.362Ca++ (mmol/L)1.39 (1.36; 1.43)1.25 (1.21; 1.28)< 0.0011.41 (1.38; 1.50)1.22 (1.18; 1.24)< 0.0010.004Phosphate (mmol/L)0.70 (0.57; 0.83)1.03 (0.90; 1.17)< 0.0010.64 (0.57; 0.74)1.04 (0.95; 1.25)< 0.0010.26525(OH)D (nmol/L)38.9 (26.8; 47.4)76.1 (61.6; 84.3)< 0.00139.8 (29.8; 52.1)67.9 (54.7; 83.4)< 0.0010.3521,25(OH)D (nmol/L)62.0 (49.0; 77.0)46.0 (40.0; 65.0)0.01757.0 (41.0; 73.0)57.0 (41.0; 73.0)0.0110.525BAP (ng/mL)20.4 (14.6; 28.3)11.4 (8.1; 12.4)0.0115.9 (10.8; 27.7)9.3 (8.1; 12.1)0.0010.410OC (ng/mL)41.8 (22.8; 59.6)14.9 (12.7; 20.8)< 0.00133.2 (25.2; 43.3)14.3 (11.6; 17.8)< 0.0010.519CTX (ng/mL)0.84 (0.42; 1.01)0.19 (0.15; 0.28)< 0.0010.63 (0.52; 0.79)0.16 (0.14; 0.24)< 0.0010.366P1NP (ng/mL)61.5 (47.0; 89.0)24.0 (20.0; 31.0)< 0.00152.0 (43.0; 74.5)24.0 (22.0; 31.0)< 0.0010.89024 h CrCl (mL/min)107.7 (96.4; 132.8)91.4 (78.9; 129.0)0.05121.6 (89.4; 161.5)112.6 (90.6; 136.2)0.1940.113OPG (pmol/L)4.46 (3.64; 5.64)4.97 (3.57; 7.48)0.0874.65 (3.63; 5.47)5.05 (3.38; 6.27)0.9760.525RANKL (pmol/L)0.87 (0.51; 1.42)0.58 (0.37; 1.35)0.4650.74 (0.52; 0.99)0.65 (0.42; 0.94)0.0681SOST (pmol/L)19.63 (15.55; 29.31)20.33 (16.16; 41.01)0.04320.84 (14.85; 28.49)21.28 (18.42; 29.01)0.1210.920DKK-1 (pmol/L)25.10 (18.99; 35.69)34.07 (20.06; 39.39)0.00832.32 (23.71; 41.04)34.40 (29.39; 45.43)0.0210.221PTH parathyroid hormone, Ca++ ionized calcium, 25(OH)D 25-hydroxyvitamin D, 1,25(OH)D 1,25-dihydroxyvitamin D, BAP bone-specific alkaline phosphatase, OC osteocalcin, CTX CrossLaps, P1NP procollagen type 1 N-terminal propeptide, 24 h CrCl measured 24-h creatinine clearance, OPG osteoprotegerin, RANKL receptor activator of nuclear factor-kappa ligand, SOST sclerostin, DKK-1 Dickkopf-1
Source: Change in biochemical parameters. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Source: Article title.
Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Source: Article title.
In this randomized, placebo-controlled, double-blind trial, 52 patients were treated with strontium ranelate 2 g daily + 1000 mg calcium + 800 IU vitamin D (strontium group; SG) or with 1000 mg calcium + 800 IU vitamin D alone (placebo group; PG) for 1 year.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Randomised controlled trial · Langenbeck's Archives of Surgery · 2019
Original publication title
Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
© The Author(s) 2019
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
After successful surgery for primary hyperparathyroidism, bone mineral density (BMD) does not improve equally in all patients. As no trial has so far aimed to influence normalization of BMD, it was the goal of this investigation to determine whether pharmacological treatment is effective in improving regain of BMD after successful parathyroidectomy in patients with preoperatively diagnosed osteoporosis or osteopenia and to evaluate when treatment may be indicated.
Source: PurposeAbstract: What methods does the paper describe?
In this randomized, placebo-controlled, double-blind trial, 52 patients were treated with strontium ranelate 2 g daily + 1000 mg calcium + 800 IU vitamin D (strontium group; SG) or with 1000 mg calcium + 800 IU vitamin D alone (placebo group; PG) for 1 year. The main outcome measures were BMD (lumbar spine, femoral neck, radius) and bone turnover markers.
Source: MethodsAbstract: Electronic supplementary material
The online version of this article (10.1007/s00423-019-01815-9) contains supplementary material, which is available to authorized users.
Source: Electronic supplementary materialAbstract: Results
The baseline characteristics were similar in both groups. Absolute BMD (1.007 ± 0.197 vs. 0.897 ± 0.137 g/cm2; p = 0.024) and both relative (9.94 vs. 3.94%; p < 0.001) and absolute (0.09 ± 0.06 vs. 0.03 ± 0.04 g/cm2; p < 0.001) changes in lumbar-spine BMD were significantly higher in the SG than in the PG. Compared to baseline, BMD significantly increased in both groups at the lumbar spine (p < 0.001 and p = 0.001, respectively) and femoral neck (both p < 0.001), whereas radius BMD only changed significantly in the SG.
However, the proportion of patients with osteoporosis/osteopenia significantly declined only at the lumbar spine in the SG (from 69.0 to 37.9%; p = 0.034), whereas no decrease was found in the PG. No severe adverse events occurred.
Source: ResultsAbstract: Conclusions
Postoperative anti-osteoporotic treatment can positively influence regain of BMD mainly in the lumbar spine and should be considered. Without treatment, most patients and especially those with low preoperative markers of bone turnover remained osteoporotic/osteopenic 1 year after surgery.
Source: ConclusionsAuthors’ abstract
Purpose
After successful surgery for primary hyperparathyroidism, bone mineral density (BMD) does not improve equally in all patients. As no trial has so far aimed to influence normalization of BMD, it was the goal of this investigation to determine whether pharmacological treatment is effective in improving regain of BMD after successful parathyroidectomy in patients with preoperatively diagnosed osteoporosis or osteopenia and to evaluate when treatment may be indicated.
Methods
In this randomized, placebo-controlled, double-blind trial, 52 patients were treated with strontium ranelate 2 g daily + 1000 mg calcium + 800 IU vitamin D (strontium group; SG) or with 1000 mg calcium + 800 IU vitamin D alone (placebo group; PG) for 1 year. The main outcome measures were BMD (lumbar spine, femoral neck, radius) and bone turnover markers.
Results
The baseline characteristics were similar in both groups. Absolute BMD (1.007 ± 0.197 vs. 0.897 ± 0.137 g/cm2; p = 0.024) and both relative (9.94 vs. 3.94%; p < 0.001) and absolute (0.09 ± 0.06 vs. 0.03 ± 0.04 g/cm2; p < 0.001) changes in lumbar-spine BMD were significantly higher in the SG than in the PG. Compared to baseline, BMD significantly increased in both groups at the lumbar spine (p < 0.001 and p = 0.001, respectively) and femoral neck (both p < 0.001), whereas radius BMD only changed significantly in the SG.
However, the proportion of patients with osteoporosis/osteopenia significantly declined only at the lumbar spine in the SG (from 69.0 to 37.9%; p = 0.034), whereas no decrease was found in the PG. No severe adverse events occurred.
Conclusions
Postoperative anti-osteoporotic treatment can positively influence regain of BMD mainly in the lumbar spine and should be considered. Without treatment, most patients and especially those with low preoperative markers of bone turnover remained osteoporotic/osteopenic 1 year after surgery.
Electronic supplementary material
The online version of this article (10.1007/s00423-019-01815-9) contains supplementary material, which is available to authorized users.
Publication and source details
Original title: Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Martin B. Niederle; Ursula Foeger-Samwald; Philipp Riss; Andreas Selberherr; Christian Scheuba; Peter Pietschmann; Bruno Niederle; Katharina Kerschan-Schindl
Langenbeck's Archives of Surgery · 2019
© The Author(s) 2019https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.http://dx.doi.org/10.13039/501100004061Oesterreichische Nationalbank13245Kerschan-Schindl KatharinaRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T19:14:01.748993+00:00
DOI: 10.1007/s00423-019-01815-9 · PMC6906217